GGrantIndex
← Leaderboards

David M. Nanus

Weill Medical College Of Cornell Univ

$4,374,762
Attributed
$4,374,762
Total exposure
8
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $736.3K · FY200507
$1M$750K$500K$250K$0
'05
'06
'07

Funding mix

By agency

NIH$4,374,762 · 8

By mechanism

R01$3,685,586 · 2
K24$623,522 · 1
M01$65,654 · 5

Top collaborators

No co-investigators on record.

Most similar at Weill Medical College Of Cornell Univ

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectProstate NeoplasmsClinical ResearchClinical Trial Phase IHuman Therapy EvaluationLaboratory MouseRetinoateNeoplasm /Cancer ChemotherapyMonoclonal AntibodyNeoplasm /Cancer ImmunotherapyLiposomesNutrition Related TagMaleNeoplasm /Cancer GeneticsMetastasisCombination Cancer TherapyDrug Screening /EvaluationTissue /Cell CultureProstate Specific AntigenNeoplastic ProcessPatient Oriented ResearchCell Growth RegulationCarcinogenesisAntitumor Antibody

Grant awards (21)

PHASE II TRIAL OF 177LU-J591 IN METASTATIC, ANDROGEN-INDEPENDENT PROSTATE CANCER$3,510
M01 · FY2007 · RR · contact PI
PHASE I TRIAL OF ATRA-IV & DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES$8,914
M01 · FY2006 · RR · contact PI
Modulation of retinoic acid action in renal cancer$381,213
R01 · FY2005 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2005 · CA
PHASE I TRIAL OF ATRA-IV &DEPAKOTE IN PTS W/ADVANCED SOLID TUMOR MALIGNANCIES$36,440
M01 · FY2005 · RR
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2004 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2004 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$130,580
K24 · FY2004 · CA
Phase I 111-Indium radiolabeled mAb huJ591/ metastatic solid tumors$15,988
M01 · FY2004 · RR
Chemoprevention of Prostate Cancer with Finasteride$802
M01 · FY2004 · RR
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2003 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2003 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$127,562
K24 · FY2003 · CA
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2002 · CA
Neutral Endopeptidase inactivation in advanced prostate$318,660
R01 · FY2002 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$124,634
K24 · FY2002 · CA
Modulation of retinoic acid action in renal cancer$351,713
R01 · FY2001 · CA
NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE$316,044
R01 · FY2001 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$121,790
K24 · FY2001 · CA
NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE$306,837
R01 · FY2000 · CA
ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES$118,956
K24 · FY2000 · CA